ORIGINAL RESEARCH article

Front. Oncol., 26 July 2023

Sec. Cancer Imaging and Image-directed Interventions

Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1117148

Feasibility of accelerated T2 mapping for the preoperative assessment of endometrial carcinoma

  • 1. Department of Magnetic Resonance Imaging, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

  • 2. Magnetic Resonance Collaboration, Siemens Healthcare Ltd., Beijing, China

  • 3. Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, Switzerland

  • 4. Signal Processing Lab 5 (LTS5), Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

  • 5. Department of Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Abstract

Objective:

The application value of T2 mapping in evaluating endometrial carcinoma (EMC) features remains unclear. The aim of the study was to determine the quantitative T2 values in EMC using a novel accelerated T2 mapping, and evaluate them for detection, classification,and grading of EMC.

Materials and methods:

Fifty-six patients with pathologically confirmed EMC and 17 healthy volunteers were prospectively enrolled in this study. All participants underwent pelvic magnetic resonance imaging, including DWI and accelerated T2 mapping, before treatment. The T2 and apparent diffusion coefficient (ADC) values of different pathologic EMC features were extracted and compared. Receiver operating characteristic (ROC) curve analysis was performed to analyze the diagnostic efficacy of the T2 and ADC values in distinguishing different pathological features of EMC.

Results:

The T2 values and ADC values were significantly lower in EMC than in normal endometrium (bothl p < 0.05). The T2 and ADC values were significantly different between endometrioid adenocarcinoma (EA) and non-EA (both p < 0.05) and EMC tumor grades (all p < 0.05) but not for EMC clinical types (both p > 0.05) and depth of myometrial invasion (both p > 0.05). The area under the ROC curve (AUC) was higher for T2 values than for ADC values in predicting grade 3 EA (0.939 vs. 0.764, p = 0.048). When combined T2 and ADC values, the AUC for predicting grade 3 EA showed a significant increase to 0.947 (p = 0.03) compared with those of ADC values. The T2 and ADC values were negatively correlated with the tumor grades (r = -0.706 and r = -0.537, respectively).

Conclusion:

Quantitative T2 values demonstrate potential suitability in discriminating between EMC and normal endometrium, EA and non-EA, grade 3 EA and grade 1/2 EA. Combining T2 and ADC values performs better in predicting the histological grades of EA in comparison with ADC values alone.

1 Introduction

Endometrial carcinoma (EMC) is a common malignant tumor of the female reproductive system and has continued increasing incidence and mortality rates worldwide (1). The treatment strategies and survival outcomes of patients with EMC are associated with the histologic and pathologic grades of EMC, the status of myometrial invasion depths, cervical stromal invasion, and lymph node metastases (2). Magnetic resonance imaging (MRI) is a common and standard imaging modality for EMC’s diagnosis and preoperative staging (3). Diagnoses based on conventional MRI rely on comparing signal intensities from different tissues, which can be easily affected by equipment variability and scan parameters. Quantitative MRI methods, such as diffusion-tensor imaging, dynamic contrast-enhanced analysis, and amide proton transfer-weighted MRI, have been used for clinical diagnoses, tumor progression, and treatment responses of patients with EMC (4–7).

T2 mapping is a quantitative MRI method that measures the transverse relaxation time (T2) of various tissues, which is displayed as image voxels on parametric maps (8). The T2 or transverse relaxation time is related to the lifetime of the magnetization component in the plane perpendicular to the magnetic field direction, which is zero at equilibrium. Conventional T2 mapping is performed with a multiplanar multiecho spin echo sequence, which requires long scan times to acquire the entire k-space. GRAPPATINI is an accelerated T2 mapping method that significantly shortens T2 mapping times by combining the generalized auto-calibrating partially parallel acquisition (GRAPPA) technique with the model-based accelerated relaxometry by iterative nonlinear inversion (MARTINI) technique using k-space undersampling (9). The efficacy of the accelerated T2 mapping technique has been reported for the prostate, cervix, pancreas, rectum, and knee (8, 10–12). E.g., Mai et al. assessed quantitative T2 values derived from accelerated T2 mapping to diagnose and grade prostate cancer. Diverse T2 values were observed between different grades of prostate cancer and suggested that quantitative T2 values may help discriminate malignant lesions from other benign pathologies (10). Moreover, Li and colleagues used accelerated T2 mapping and diffusion measures for evaluating cervical cancer (CC) classification, grade and lymphovascular space invasion (LVSI), finding lower quantitative T2 values in poorly differentiated CC and LVSI-positive CC (8). However, the clinical value of this technique in EMC remains unclear.

This study aimed to determine the quantitative T2 values for endometrial cancer and normal endometrium using a novel accelerated T2 mapping, and their evaluation with regard to detection, classification, and grading of endometrial cancer in comparison to the corresponding apparent diffusion coefficient (ADC) value.

2 Materials and methods

2.1 Study participants

This prospective study was approved by the institutional review board of our hospital. Written informed consent was obtained from all study participants. This study included 109 patients who were diagnosed with EMC between December 2019 and October 2021 at our hospital. The inclusion criteria were as follows: (1) patients without dilation and curettage, surgery, or other related treatments before the MRI examination; (2) patients suspected of having EMC; (3) patients with data from all MRI sequences relevant to this study; (4) patients that underwent surgical treatment within two weeks after the MRI examination; and (5) patients with a confirmation of EMC based on the histopathologic examination after surgery. The exclusion criteria were as follows: (1) patients with small lesions (n = 15), (2) poor image quality that did not meet the requirements for analysis (n = 12), (3) histologic subtype or pathologic grading that could not be determined by the histopathologic examination (n = 15), and (4) patients treated with radiotherapy and chemotherapy before the MRI examination (n = 11). Finally, 56 patients (mean age: 55 ± 7 years; range: 27–64 years) were enrolled in the study. Among these, 35.7% (20/56) were premenopausal women, and 64.3% (36/56) were postmenopausal women. The mean time interval between MRI acquisitions and surgery was 7.5 days (range: 2–14 days). The study also included 17 age-matched healthy volunteers during the same period, and none of the volunteers showed any abnormalities in the uterus or adnexa according to the ultrasound or MRI examinations. The mean age of the volunteers was 53 ± 10 years (range: 27–64 years). Among the 17 healthy volunteers, 41.2% (7/17) were premenopausal women, and 58.8% (10/17) were postmenopausal women.

2.2 Image acquisition

The pelvic MRI examinations were performed using a 3T MRI scanner (MAGNETOM Skyra, Erlangen, Germany) equipped with an 18-channel phased-array body coil. The patients were scanned in a head-first supine position. All patients of childbearing age and healthy volunteers underwent MRI examinations between days 5 and 14 after the end of menses, whereas the timing of the MRI examination was not restricted for the menopausal patients and the healthy volunteers (13). The patients were instructed to fast for four to six hours before the MRI acquisition. The MRI scans were performed bilaterally from the superior margin of the iliac wing to the level of the femoral neck by using the conventional T2-weighted turbo spin echo sequence, DWI, and a prototypic T2 mapping sequence. In three diffusion directions, DWI was acquired using an echo planar sequence with b-values of 50 and 1000 s/mm2. T2 mapping was performed using the prototypic multiecho sequence accelerated 10-fold with the GRAPPATINI technique by using a parallel imaging factor of 2 and an undersampling factor of 5. The apparent diffusion coefficient (ADC) and T2 parametric maps were automatically generated inline after data acquisition. The MRI sequence parameters are shown in Table 1.

Table 1

ParametersConventional T2W TSE imagingDiffusion-weighted EPIGRAPPATINI-accelerated T2 mapping
TR (ms)300039104680
TE (ms)1165710, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160
Field of view (mm2)180×180320×240220×220
Slice thickness (mm)444
Matrix384×288192×144320×240
Flip angle (°)160180180
Bandwidth (Hz/pixel)2001002195
Acquisition time3 min 20 s1 min 58 s4 min 17 s

Magnetic resonance imaging acquisition parameters.

T2W, T2-weighted; TSE, turbo spin-echo; EPI, echo-planar imaging; TR, repetition time; TE, echo time; GRAPPATINI, combined generalized autocalibrating partially parallel acquisition and model-based acceleration by iterative nonlinear inversion.

2.3 Image analysis and measurements

The data analysis of all MRI images was performed using syngo.via software (Erlangen, Germany). Two radiologists with eight and five years of experience in pelvic MRI independently performed the quantitative analysis by using the double-blinded method. Statistical analysis was performed using the average values of the measurements by the two radiologists. The EMC lesions, junctional zone (JZ), and outer myometrium (OMM) were identified on the ADC and the T2 maps on the basis of the T2-weighted imaging (T2WI) and DWI scans, respectively. The regions of interest (ROIs) were manually drawn for the EMC lesions, JZ, and OMM of all patients with EMC, and each ROI included more than 25 pixels. Furthermore, the shape and position of the ROIs on the ADC and the T2 maps were consistent. The ROIs for the EMC lesions were drawn along the largest cross-section of the lesions. In the case of thin or unclear JZ, the ROIs were drawn around the muscle tissue adjacent to the EMC lesion (medial 50% of the muscle layer) (14). The cystic, necrotic, and hemorrhagic areas were avoided as much as possible while drawing the ROIs. Normal endometrial ROIs were drawn for healthy individuals by using the T2WI scans as references. An elliptical ROI was drawn on the ADC and T2 maps along the largest section where the endometrium was clearly visible.

2.4 Pathologic evaluation

All 56 patients with EMC underwent standard surgery consistent with the current FIGO staging criteria (15). The histopathology of all the surgical specimens was evaluated by a pathologist with >10 years of experience, who was blinded to the results from the MRI diagnosis. The histopathologic subtypes, pathologic grading, and myometrial invasion depth of the surgical specimens were used as the reference standards.

2.5 Statistical analysis

SPSS 21.0 (IBM Corp., Armonk, NY, USA) and MedCalc (MedCalc Software, Mariakerke, Belgium) were used for the statistical analyses. The Shapiro–Wilk normality test was used to determine normal or skewed data distribution for each group. The nonnormally distributed data were compared using the Kruskal–Wallis H test and the Mann–Whitney U test, and the Bonferroni correction method was used to obtain the adjusted p values. Receiver operating characteristic (ROC) curve analysis was performed to analyze the diagnostic efficacy of the T2 and ADC values. Each parameter’s discriminating power was quantified using the area under the ROC curve (AUC). The DeLong test was performed to compare the differences in the diagnostic efficacy of each parameter. Pearson’s correlation coefficient was used to evaluate the correlation between the T2 and ADC values. Spearman correlation was applied to analyze the association between the T2 and ADC values with different histological grades. The intraclass correlation coefficient (ICC) was used to evaluate the agreement in the quantitative measurements between the two radiologists, in which ICC ≥ 0.75 was considered a good agreement. Also, a p value < 0.05 was considered statistically significant.

3 Results

3.1 Patient characteristics

This study enrolled 56 patients with a postoperative pathologic diagnosis of EMC and 17 healthy volunteers. The mean ages of the patients with EMC (55 ± 7 years) and healthy volunteers (53 ± 10 years) were not significantly statistically different (t = 0.821; p = 0.421). The clinical characteristics of the patients are shown in Table 2.

Table 2

CharacteristicsNumber of patients
Pathology
 Endometrioid adenocarcinoma46
 Mucinous adenocarcinoma2
 Serous adenocarcinoma3
 Clear cell carcinoma1
 Carcinosarcoma2
 Undifferentiated carcinoma2
Clinical type
 Type I36
 Type II20
Histologic grade
 Well-differentiated (G1)19
 Moderately differentiated(G2)17
 Poorly differentiated(G3)10
Myometrial invasion
 Superficial (<50%)40
 Deep (≥50%)16
FIGO stage
 IA27
 IB12
 II9
 IIIA3
 IIIC14
 IV1

Clinical characteristics of the 56 enrolled patients with endometrial carcinoma.

FIGO, International Federation of Gynecology and Obstetrics.

3.2 T2 values and ADC values of the uterine wall, normal endometrium, and EMC

The T2 and ADC values of the uterine wall, normal endometrium, and EMC are shown in Table 3 and Figure 1. The T2 values of the EMC were significantly lower than those for the normal endometrium (p = 0.002) and significantly higher than those for the JZ (p < 0.001); however, significant differences were not observed between the T2 values of the EMC and the OMM (p = 0.845) (Figure 1A). Also, the T2 values of the JZ were significantly lower than those of the EMC, OMM, and normal endometrium (all p < 0.001) (Figure 2). The ADC values of the EMC were significantly lower than the ADC values of the uterine wall layers and normal endometrium (all p < 0.001) (Figure 1B). In addition, the ADC values of the JZ were significantly lower than those of the normal endometrium and OMM (both p < 0.001). Further, the ICC analysis showed a good agreement between the two radiologists for the T2 and ADC values of the EMC, normal endometrium, JZ, and OMM (Table 3).

Table 3

TissueT2 (ms)ADC (×10-3mm2/s)Intraclass Correlation Coefficient
(ICC, 95% confidence interval)
T2 valueADC
NEM152.0 ± 58.0a1.52 ± 0.50a0.881 (0.759,0.943)0.851 (0.703,0.928)
JZ58.6 ± 9.9a0.97 ± 0.13a0.934 (0.709,0.986)0.942 (0.739,0.988)
OMM81.8 ± 12.41.24 ± 0.19a0.798 (0.610,0.901)0.793 (0.600,0.898)
EMC86.8 ± 10.40.73 ± 0.130.854 (0.709,0.930)0.806 (0.623,0.905)

T2 and ADC values for NEM, JZ, OMM, and EMC.

a

Significantly different from the corresponding value of EMC.

T2, transverse relaxation time; ADC, apparent diffusion coefficient; EMC, endometrial carcinoma; JZ, junctional zone; OMM, outer myometrium; NEM, normal endometrium.

Figure 1

Figure 2

3.3 Comparison of T2 values and ADC values of the different pathologic features

As shown in Table 4, the T2 and ADC values between types I and II EMC(p = 0.266 and p = 0.245, respectively),and between superficial and deep myometrial invasion (p = 0.793 and p = 0.235, respectively) did not show any statistically significant differences. The T2 and ADC values of the endometrioid adenocarcinoma (EA) were significantly lower than those of the non-EA tumors (p = 0.003 and p = 0.043, respectively). Moreover, a quantitative analysis of the EA tumors with different pathologic grades demonstrated that the T2 values were significantly lower for grade 3 (G3) EA than those for grade 1 (G1) EA or grade 2 (G2) EA (both p < 0.017) (Figure 3; Table 4). However, the differences in the T2 values between the G1 EA and G2 EA were not statistically significant (p > 0.05). Furthermore, the ADC values for the G3 EA were significantly lower than those for the G1 EA (p < 0.017; Table 4).

Table 4

GroupsT2 (ms)ADC (×10-3mm2/s)
Tissue type
 endometrial carcinoma(n=56)86.8 ± 10.41.52 ± 0.50
 normal endometrium(n=17)152.0 ± 58.00.73 ± 0.13
P< 0.001< 0.001
Clinical type
 Type I (n=36)87.9 ± 8.70.71 ± 0.09
 Type II (n=20)85.0 ± 13.10.77 ± 0.18
P0.2660.245
Pathologic type
 EA (n=46)84.9 ± 8.960.71 ± 0.10
 Non-EA (n=10)94.9 ± 10.50.84 ± 0.19
P0.0030.043
Tumor grade (EA)
 Grade 1 (n=19)91.0 ± 9.10.76 ± 0.08
 Grade 2 (n=17)83.8 ± 3.10.70 ± 0.09
 Grade 3 (n=10)75.0 ± 5.6ab0.64 ± 0.06a
P< 0.0010.002
Myometrial invasion
 Superficial (n=40)87.1 ± 9.20.76 ± 0.14
 Deep (n=16)85.6 ± 11.90.71 ± 0.11
P0.7930.235

T2 and ADC values of the clinical types, pathologic types, and grades of EMC.

a

P < 0.017 (significantly different from grade 1); bP < 0.017 (significantly different from grade 2).

ADC, apparent diffusion coefficient; EMC, endometrial carcinoma; EA endometrioid adenocarcinoma.

Figure 3

3.4 Comparison of ROC curves

The threshold, AUC, p value, sensitivity, and specificity of T2 and ADC values discriminating three categories (EMC/normal, EA/non-EA, and tumor grade) are listed in Table 5. The AUC values for the T2 and ADC values in distinguishing between the EMC and normal endometrium were 0.944 and 0.987, respectively (Figures 4A and 5), with no significant difference (DeLong test: Z = 1.212; p = 0.226). When combined T2 and ADC values, the AUC showed a slight increase to 0.992 with no significant difference (p = 0.160 and 0.390, respectively). The AUC values for the T2 and ADC values in distinguishing between the EA and non-EA tumors were 0.798 and 0.705, respectively (Figure 4B), with no significant difference(DeLong test: Z = 0.851; p = 0.395). When combined T2 and ADC values, the AUC showed a slight increase to 0.817 with no significant difference (p = 0.663 and 0.125, respectively).The AUC values for predicting G3 EA were 0.939 for the T2 values and 0.764 for the ADC values (Figure 4C). According to the DeLong test, these differences were statistically significant (Z=1.972; p = 0.048), that is, however,slightly less significant. When combined T2 and ADC values, the AUC showed a significant increase to 0.947 compared with the ADC values (p = 0.03, Figure 4C).

Table 5

CategorythresholdAUC (95%CI)P-valueSensitivitySpecificity
EMC vs normal
T2 values (ms)101.70.944 (0.864 - 0.984)< 0.00189.3%84.2%
ADC values (×10-3mm2/s)0.960.987 (0.928 - 1.000)< 0.00192.9%100%
CombinedNA0.992 (0.935 - 1.000)< 0.00192.9%100%
EA vs Non-EA
T2 values (ms)87.80.798 (0.669-0.893)< 0.00176.1%80.0%
ADC values (×10-3mm2/s)0.940.705 (0.569-0.820)0.03100%40.0%
CombinedNA0.817 (0.691-0.908)< 0.00189.1%80.0%
G3 vs G1/2
T2 values (ms)79.50.939 (0.827-0.988)< 0.00190.0%94.4%
ADC values (×10-3mm2/s)0.710.764 (0.616-0.876)< 0.0190.0%52.8%
CombinedNA0.947 (0.838-0.991)< 0.00190.0%97.2%

Diagnostic performance of T2 and ADC values.

ADC, apparent diffusion coefficient; AUC, area under the curve; CI, confidence interval; EA, endometrioid adenocarcinoma; NA, not applicable.

Figure 4

Figure 5

3.5 Correlation analysis

The Pearson’s correlation analysis showed that there was a significant positive correlation between the T2 and the ADC values (r=0.347, p=0.009, Figure 6). The correlation of the histological grades with the T2 and ADC values showed a significant inverse correlation with r = -0.706 (P < 0.001) and r = -0.517 (P < 0.001), respectively.

Figure 6

4 Discussion

This study evaluated the feasibility of using accelerated T2 mapping for the preoperative evaluation of EMC. Quantitative T2 values accurately distinguished EMC from normal endometrial tissues, EA from non-EA, well/moderately differentiated (G1/G2) and poorly differentiated (G3) EA. The combination of T2 and ADC values resulted in a notable increase in the AUC for predicting grade 3 EA, when compared with ADC values alone. Furthermore, T2 values show a strong inverse correlation with pathologic EA grading(r=-0.706, P < 0.001).

Regarding uterine MRI, conventional pelvic MRI sequences have been used to characterize the signal intensity of normal endometrium, myometrium, and cancerous lesions by visual analysis. However, precise discernment is hindered when the signal difference between the cancerous lesion and adjacent tissue is small. T2 mapping can be used to analyze the changes in the composition of the tissue by measuring the T2 relaxation time, which is related to the water content in the tissue (16). Previous researchers have reported the value of T2 mapping in the detection and prediction of tumor histopathological features (16, 17), but few quantitative studies have focused on T2 mapping in EMC. In this study, T2 mapping can be used to visualize the morphological structure of the myometrium, especially the JZ. The JZ demonstrated a lower T2 value than the normal endometrium, outer myometrium, and EMC. The clear description of the uterine wall layers and EMC depends on the alternating differences in the T2 values of the individual layers, which may be caused by the considerable interlayer differences in cell density (5).

Our study demonstrated that quantitative T2 values could differentiate EMC from normal endometrium, which was consistent with tumors in other organs (8, 10, 16, 17). As for the ADC values, the same applied with the quantitative T2 values, a lower value is suspected to be cancer. The AUC for T2 and ADC values to differentiate EMC and normal endometriumwere 0.944 and 0.987, with no significant difference. This suggests that both parameters therefore seem to be equally suitable for the detection of EMC. Our result indicated that T2 had a weak positive correlation with the ADC values. As we know, ADC value is calculated through linear regression from DWI images taken at various b-values and is based on the restriction of water molecule diffusion within tissues. In contrast to ADC values, T2 values reflect the tissue composition, mainly free water content. Nevertheless, it has been demonstrated that ADC values as well as quantitative T2 values are linked to the cell density (18).

EMC is classified into EA, serous uterine carcinoma, undifferentiated carcinoma, uterine carcinosarcoma, and clear cell carcinoma by the 2014 World Health Organization Classification of Tumors of Female Reproductive Organs (15). Among these tumors, non-EA tumors are less prevalent than EA and show higher malignancy and poorer prognosis (15). The results of the current study showed that the T2 values of the non-EA group were significantly higher than those of the EA group. This may be related to the mixed tissue composition of the carcinosarcoma and the clear cell carcinoma, with the non-EA groups of EMC having more micronecrotic foci and cystic epithelial components than the EA groups of EMC (19, 20). Furthermore, extensive tumor micronecrosis in the serous uterine carcinoma and the undifferentiated carcinoma may contribute to the higher T2 values of the non-EA groups of EMC. This study showed that the diagnostic accuracy of the T2 and ADC values in distinguishing EA and non-EA tumors is comparable. However, we did not observe significant differences in the T2 and ADC values between types I and II EMCs, and between superficial and deep myometrial invasion, which was consistent with previous studies (6).

The pathologic grade of EMC is a major prognostic factor that affects the survival rates of patients with EMC (21). In the present study, only the pathologic grade of the EA tumors was analyzed because the number of non-EA cases was small in the study cohort. With regard to the ADC values, a significant inverse correlation with the EA differentiation grades has already been shown in current and previous studies (4, 7). Similarly, the quantitative T2 values decrease with increasing differentiation grades with r=0.706. Gu et al. (17) demonstrated that the T2 values for brain tumors with higher cell density were lower because of reduced extracellular space. Adams et al. (22) reported that the T2 values for high-grade renal clear cell carcinoma were significantly lower than those for low-grade renal carcinoma, and these findings were consistent with the results of the current study, in which the T2 values of G3 EA were lower and associated with reduced glandular structure and increased solid components. In addition, higher cell density and nuclear-to-cytoplasmic ratio in the G3 EA tumors decreased the extracellular space and reduced the water content in the tumor tissues. For prediction of poorly differentiated (G3) EA, T2 values yielded an AUC of 0.94, which means that the T2 mapping can provide valuable insights into the histological grades of EA. Combining the T2 value to ADC values improved the AUC by up to 0.947 with significant difference, when compared to the AUC obtained solely from ADC values for predicting G3 EA. These results point to the potential of T2 mapping to provide information complementary to that provided by DW imaging for tumor differentiation.

The T2 values in this study were obtained on the basis of a novel fast imaging technique (i.e., GRAPPATINI) with a parallel acquisition factor of two and an undersampling factor of five. The T2 maps were reconstructed with a 10-fold undersampled k-space, which significantly reduced the acquisition time and improved the clinical utility of T2 mapping. The broad clinical application of conventional T2 mapping is limited by long image acquisition times and potential motion artifacts because of patient movements. Previous studies have confirmed that the T2 values obtained with the GRAPPATINI technique are comparable with those obtained using the conventional multiecho spin echo sequence (9, 11, 23). Therefore, accelerated T2 mapping is a fast functional imaging technique that can yield accurate T2 values for quantifying the underlying pathophysiology in biological tissues within a shorter period.

This study has a few limitations. The sample size of the study cohort was small. Furthermore, the number of cases in the non-EA group were significantly low. Therefore, analysis of the T2 values for rare tumors such as serous uterine carcinoma, uterine carcinosarcoma, and undifferentiated carcinoma was not feasible. Also, future large-scale studies are necessary to confirm our results and characterize different subgroups of EMC.

In summary, our study demonstrated that the quantitative T2 values obtained from accelerated T2 mapping were useful for preoperative diagnosis and the pathologic classification and grading of EMC.

Statements

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human participants were reviewed and approved by The First Affiliated Hospital of Zhengzhou University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

TH, TK, JZ, FQ: Conceptualization, Methodology, Software, Validation. ZZ, JL, WW: Data curation, Writing- Original draft preparation and Editing. YZ, JC: Supervision.

Conflict of interest

Authors TH, TK, FQ, and JZ are employees of Siemens Healthcare.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Abbreviations

MRI, Magnetic resonance imaging; ADC, Apparent diffusion coefficient; ROC, Receiver operating characteristic; AUC, Area under the ROC curve; DWI, Diffusion-weighted imaging; EMC, Endometrial carcinoma; EA, Endometrioid adenocarcinoma; G1, Grade 1; G2, Grade 2; G3. Grade 3; ICC, Intraclass correlation coefficient; JZ, Junctional zone; OMM, Outer myometrium; T2WI, T2-weighted imaging.

References

  • 1

    MakkerVMacKayHRay-CoquardILevineDAWestinSNAokiDet al. Endometrial cancer. Nat Rev Dis Primers (2021) 7:88. doi: 10.1038/s41572-021-00324-8

  • 2

    BendifallahSOuldamerLLavoueVCanlorbeGRaimondECoutantCet al. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group. Gynecol Oncol (2017) 144:107–12. doi: 10.1016/j.ygyno.2016.10.025

  • 3

    NougaretSHortaMSalaELakhmanYThomassin-NaggaraIKidoAet al. Endometrial cancer MRI staging: updated guidelines of the European society of urogenital radiology. Eur Radiol (2019) 29:792–805. doi: 10.1007/s00330-018-5515-y

  • 4

    SattaSDolciamiMCelliVDiSFPerniolaGPalaiaIet al. Quantitative diffusion and perfusion MRI in the evaluation of endometrial cancer: validation with histopathological parameters. Br J Radiol (2021) 94:20210054. doi: 10.1259/bjr.20210054

  • 5

    YamadaIWakanaKKobayashiDMiyasakaNOshimaNWakabayashiAet al. Endometrial carcinoma: Evaluation using diffusion-tensor imaging and its correlation with histopathologic findings. J Magn Reson Imaging (2019) 50:250–60. doi: 10.1002/jmri.26558

  • 6

    KelesDKEvrimlerSMerdNErdemogluE. Endometrial cancer: the role of MRI quantitative assessment in preoperative staging and risk stratification. Acta Radiol (2022) 63(8):1126–33. doi: 10.1177/028418512110258537

  • 7

    ChenTLiYLuSSZhangYDWangXNLuoCYet al. Quantitative evaluation of diffusion-kurtosis imaging for grading endometrial carcinoma: a comparative study with diffusion-weighted imaging. Clin Radiol (2017) 72:995.e11–995.e20. doi: 10.1016/j.crad.2017.07.004

  • 8

    LiSLiuJZhangFYangMZhangZLiuJet al. Novel T2 mapping for evaluating cervical cancer features by providing quantitative T2 maps and synthetic morphologic images: A preliminary study. J Magn Reson Imaging (2020) 52:1859–69. doi: 10.1002/jmri.27297

  • 9

    RaudnerMSchreinerMHilbertTKoberTWeberMWindhagerRet al. Accelerated T2 mapping of the lumbar intervertebral disc: Highly undersampled K-space data for robust T2 relaxation time measurement in clinically feasible acquisition times. Invest Radiol (2020) 55:695–701. doi: 10.1097/RLI.0000000000000690

  • 10

    MaiJAbubrigMLehmannTHilbertTWeilandEGrimmMOet al. T2 Mapping in prostate cancer. Invest Radiol (2019) 54:146–52. doi: 10.1097/RLI.0000000000000520

  • 11

    Vietti VioliNVHilbertTBastiaansenJAMKnebelJFLedouxJBStemmerAet al. Patient respiratory-triggered quantitative T2 mapping in the pancreas. J Magn Reson Imaging (2019) 50:410–6. doi: 10.1002/jmri.26612

  • 12

    RouxMHilbertTHussamiMBecceFKoberTOmoumiP. MRI T2 mapping of the knee providing synthetic morphologic images: Comparison to conventional turbo spin-echo MRI. Radiology (2019) 293:620–30. doi: 10.1148/radiol.2019182843

  • 13

    HeYLDingNLiYLiZXiangYJinZYet al. Cyclic changes of the junctional zone on 3 T MRI images in young and middle-aged females during the menstrual cycle. Clin Radiol (2016) 71:341–8. doi: 10.1016/j.crad.2015.12.005

  • 14

    GhoshASinghTBaggaRSrinivasanRSinglaVKhandelwalN. T2 relaxometry mapping in demonstrating layered uterine architecture: Parameter optimization and utility in endometrial carcinoma and adenomyosis: A feasibility study. Br J Radiol (2018) 91:20170377. doi: 10.1259/bjr.20170377

  • 15

    ColomboNPretiELandoniFCarinelliSColomboAMariniCet al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 24:vi33–8. doi: 10.1093/annonc/mdt353

  • 16

    LiSZhangZLiuJZhangFYangMLuHet al. The feasibility of a radial turbo-spin-echo T2 mapping for preoperative prediction of the histological grade and lymphovascular space invasion of cervical squamous cell carcinoma. Eur J Radiol (2021) 139:109684. doi: 10.1016/j.ejrad.2021.109684

  • 17

    GuWFangSHouXMaDLiS. Exploring diagnostic performance of T2 mapping in diffuse glioma grading. Quant Imaging Med Surg (2021) 11:2943–54. doi: 10.21037/qims-20-916

  • 18

    LangerDLvan der KwastTHEvansAJSunLYaffeMJTrachtenbergJet al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2–sparse versus dense cancers. Radiology (2008) 249(3):900–8. doi: 10.1148/radiol.2493080236

  • 19

    MengNWangXSunJHuangZYangZShangJet al. Evaluation of amide proton transfer-weighted imaging for endometrial carcinoma histological features: A comparative study with diffusion kurtosis imaging. Eur Radiol (2021) 31:8388–98. doi: 10.1007/s00330-021-07966-y

  • 20

    BakirVLBakirBSanliSYildizSOIyibozkurtACKartalMGet al. Role of diffusion-weighted MRI in the differential diagnosis of endometrioid and non-endometrioid cancer of the uterus. Acta Radiol (2017) 58:758–67. doi: 10.1177/0284185116669873

  • 21

    ParkJJKimCKChoSWKimJH. Utility of diffusion-weighted imaging in association with pathologic upgrading in biopsy-proven grade I endometrial cancer. J Magn Reson Imaging (2020) 51:117–23. doi: 10.1002/jmri.26840

  • 22

    AdamsLCBressemKKJurmeisterPFahlenkampULRallaBEngelGet al. Use of quantitative T2 mapping for the assessment of renal cell carcinomas: First results. Cancer Imaging (2019) 19:35. doi: 10.1186/s40644-019-0222-8

  • 23

    HilbertTSumpfTJWeilandEFrahmJThiranJPMeuliRet al. Accelerated T2 mapping combining parallel MRI and model-based reconstruction: GRAPPATINI. J Magn Reson Imaging (2018) 48:359–68. doi: 10.1002/jmri.25972

Summary

Keywords

endometrial cancer, T2 mapping, magnetic resonance imaging, diffusion weighted, apparent diffusion coefficient

Citation

Zhang Z, Liu J, Wang W, Zhang Y, Qu F, Hilbert T, Kober T, Cheng J, Li S and Zhu J (2023) Feasibility of accelerated T2 mapping for the preoperative assessment of endometrial carcinoma. Front. Oncol. 13:1117148. doi: 10.3389/fonc.2023.1117148

Received

08 December 2022

Accepted

07 July 2023

Published

26 July 2023

Volume

13 - 2023

Edited by

Lucia Manganaro, Sapienza University of Rome, Italy

Reviewed by

Tae Hoon Kim, University of Missouri, United States; Silvia Capuani, National Research Council (CNR), Italy

Updates

Copyright

*Correspondence: Shujian Li, ; Jingliang Cheng,

†These authors have contributed equally to this work and share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics